You are here

gastric cancer

Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer

Merck Expands Keytruda’s Label as a First-Line Option for Gastric Cancer

BioSpace

Flag link:

Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer

Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer

Xtalks

Flag link:

BeiGene's gastric cancer drug succeeds in late-stage trial

BeiGene's gastric cancer drug succeeds in late-stage trial

Reuters

clinical trials

Flag link:

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Drugs.com

clinical trials

Flag link:

AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences

Medical Marketing and Media

antibody-drug conjugate

KYM Biosciences

Flag link:

Astellas’ Phase III gastric cancer therapy trial meets primary endpoint

Astellas’ Phase III gastric cancer therapy trial meets primary endpoint

Clinical Trials Arena

clinical trials

Flag link:

Astellas' $1.3B antibody strikes first in hot cancer field, extending survival in phase 3

Astellas' $1.3B antibody strikes first in hot cancer field, extending survival in phase 3

Fierce Biotech

clinical trials

Flag link:

Hutchmed reports positive data from gastric cancer therapy trial

Hutchmed reports positive data from gastric cancer therapy trial

Clinical Trials Arena

clinical trials

Flag link:

Elevation Oncology dips its toes into ADCs, adding second drug to its bag.

Elevation Oncology dips its toes into ADCs, adding second drug to its bag.

Endpoints

Elevation Oncology

pancreatic cancer

antibody-drug conjugate

Flag link:

Keytruda should lose stomach cancer indication, says ODAC

Keytruda should lose stomach cancer indication, says ODAC

Pharmaforum

Flag link:

Amgen's promising gastric cancer drug makes good on Five Prime potential with FDA's breakthrough nod

Amgen's promising gastric cancer drug makes good on Five Prime potential with FDA's breakthrough nod

Endpoints

clinical trials

Flag link:

Bristol Myers’ Opdivo Receives FDA Approval for Gastric Cancer

Bristol Myers’ Opdivo Receives FDA Approval for Gastric Cancer

BioSpace

Bristol Myers Squibb

Flag link:

Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal

Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal

Reuters

Five Prime Therapeutics

Flag link:

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

Endpoints

breakthrough status

metastatic gastric cancer

Flag link:

FDA fast-tracks Leap’s gastric cancer immunotherapy

FDA fast-tracks Leap’s gastric cancer immunotherapy

Pharmaforum

Leap Therapeutics

priority review

Flag link:

Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies

Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies

BioSpace

Bristol-Myers Squibb

clinical trials

esophageal cancer

Flag link:

Pieris begins gastric cancer combination trial with Lilly’s Cyramza

Pieris begins gastric cancer combination trial with Lilly’s Cyramza

Pharmaforum

Flag link:

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca to unveil key data for cancer drugs at ASCO

Pharmaforum

colorectal cancer

Flag link:

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

Pharmaceutical Business Review

breakthrough therapy

Flag link:

Macrogenics scoops its ASCO bounce

Macrogenics scoops its ASCO bounce

EP Vantage

Flag link:

Pages